Skip to main content

Advertisement

Table 3 PROs of HCV patients receiving DAAs therapy prior, during and at the end of therapy

From: Health-related quality of Life in patients with chronic hepatitis C receiving Sofosbuvir-based treatment, with and without Interferon: a prospective observational study in Egypt

Variables/Time    Friedman test Wilcoxon test
N Mean + SD Chi-Square P-value T Z P value (r)
HRQoL  
 T0 36 31.02 ± 15.30 8.35 .01 T0 - T1 = 436 -2.37 .01 (-.30)
 T1 36 39.63 ± 21.11
 T2 36 34.50 ± 19.96 T1 –T2 = 178.50 -2.04 .04(-.26)
Symptom experience
 Symptom severity
  T0 36 23.19 ± 10.21 5.41 .06 T0 - T1 = 458 -1.97 .04(-.25)
  T1 36 27.36 ± 13.07
  T2 36 24.25 ± 12.75
 Symptom hindrance
  T0 36 7.83 ± 6.40 9.89 .007 T0 - T1 = 358 -2.58 .01(-.33)
  T1 36 12.27 ± 9.00
  T2 36 10.25 ± 7.89
Mental Health
 Depression
  T0 36 8.91 ± 7.25 8.79 .01 T0 - T1 = 385 -2.28 .02(-.29)
  T1 36 10.77 ± 7.18
  T2 36 8.97 ± 6.57
 Anxiety
  T0 36 7.33 ± 5.80 6.82 .03 T0 - T1 = 379 -2.57 .01(-.33)
  T1 36 8.88 ± 5.87
  T2 36 6.86 ± 6.05 T1 - T2 = 80 -2.63 .009(-.34)
 Stress
  T0 36 10.94 ± 7.35 4.86 .08 T1 - T2 = 103.50 -2.47 .01(-.32)
  T1 36 12.05 ± 6.83
  T2 36 9.75 ± 6.80
 MSPSS
  T0 36 2.41 ± .47 11.35 .003 T0 - T1 = 212 -2.27 .02(-.29)
  T1 36 2.51 ± .37
  T2 36 2.41 ± .39 T1 - T2 = 146 -2.77 .006(-.36)
  1. HRQoL Health-related quality of life time 0, T0 time 0, T1 time 1, T2 time 2
  2. P value significant at two tailed